Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer

Bentata, Mercedes; Morgenstern, Guy; Nevo, Yuval; Kay, Gillian; Mizrahi, Avital Granit; Temper, Mark; Maimon, Ofra; Monas, Liza; Basheer, Reham; Ben-Hur, Asa; Peretz, Tamar; Salton, Maayan

doi:10.3390/genes11080880

Cited by 7 publications

(8 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 16 142 articles were identified in the aforementioned databases (Table 1). However, 234 articles were retained for full reading, following the elimination of duplicates and articles whose title and abstract did not meet the eligibility criteria; of these, only 136 12…”

Section: Resultsmentioning

confidence: 99%

“…In contrast, 26 articles reported sensitivity and specificity figures greater than 70% for combined biomarkers in the form of panels 27,29,30,61,76,77,81,82,87,90,93,94,97,98,101,104,106,111-114,118,123,124,132,147 leaving only 6 panels with figures lower than 70%. 61,76,93,114,124,132 Finally, 27 articles reported AUC and P values, 26,62,63,67,71,72,78,83,84,88,102,110,116,120,122,125,127,130,133,135,137,139,140,142,143,145,146 and of these, AUC was lower than 0.7 67,133,1...…”

Section: Discussionmentioning

confidence: 99%

“…Additional body fluids analyzed included urine 69,74,86 and saliva. 71,120 Regarding the different LB methods, miRNA analysis (56.8%) predominated, followed by cfDNA (20.5%), in the studies that used blood samples. In those that analyzed saliva or urine, the diagnosis was performed by miRNA analysis.…”

Section: Diagnostic Role Of Lb In Bcmentioning

confidence: 99%

See 2 more Smart Citations

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Duque

Manterola

Otzen

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common neoplasm in women worldwide. Liquid biopsy (LB) is a non-invasive diagnostic technique that allows the analysis of biomarkers in different body fluids, particularly in peripheral blood and also in urine, saliva, nipple discharge, volatile respiratory fluids, nasal secretions, breast milk, and tears. The objective was to analyze the available evidence related to the use of biomarkers obtained by LB for the early diagnosis of BC. Methods: Articles related to the use of biomarkers for the early diagnosis of BC due to LB, published between 2010 and 2022, from the databases (WoS, EMBASE, PubMed, and SCOPUS) were included. The MInCir diagnostic scale was applied in the articles to determine their methodological quality (MQ). Descriptive statistics were used, as well as determination of weighted averages of each variable, to analyze the extracted data. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) are described. Results: In this systematic review (SR), 136 articles met the selection criteria, representing 17 709 patients with BC. However, 95.6% were case-control studies. In 96.3% of cases, LB was performed in peripheral blood samples. Most of the articles were based on microRNA (miRNA) analysis. The mean MQ score was 25/45 points. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) have been found. Conclusions: The determination of biomarkers through LB is a useful mechanism for the diagnosis of BC. The analysis of miRNA in peripheral blood is the most studied methodology. Our results indicate that LB has a high sensitivity and specificity for the diagnosis of BC, especially in early stages.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Duque

Manterola

Otzen

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

show abstract

“…Saliva is a body fluid that can be collected easily, quickly, and non-invasively ( 140 ). Biomolecules in saliva have been used as promising markers for early diagnosis, detection, and treatment in OSCC ( 141 , 142 ), breast cancer ( 143 , 144 ), OC ( 145 ), and other tumors. In OSCC, saliva is the body fluid that has the closest contact with oral tumors.…”

Section: Salivamentioning

confidence: 99%

HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers

Wang

Zhang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

As a non-classic major histocompatibility complex (MHC) class I molecule, human leukocyte antigen G (HLA-G) is expressed in fetal-maternal interface and immunoprivileged site only in healthy condition, and in pathological conditions such as cancer, it can be de novo expressed. It is now widely accepted that HLA-G is a key molecule in the process of immune escape of cancer cells, which is ubiquitously expressed in the tumor environment. This raises the possibility that it may play an adverse role in tumor immunity. The expression level of HLA-G has been demonstrated to be highly correlated with clinical parameters in many tumors, and its potential significance in the diagnosis and prognosis of cancer has been postulated. However, because HLA-G itself has up to seven different subtypes, and for some subtypes, detected antibodies are few or absent, it is hard to evaluate the actual expression of HLA-G in tumors. In the present work, we described (a) the structure and three main forms of HLA-G, (b) summarized the mechanism of HLA-G in the immune escape of tumor cells, (c) discussed the potential role of HLA-G as a tumor marker, and reviewed (d) the methods for detecting and quantifying HLA-G.

show abstract

“… 79 Xu et al subsequently showed that the expression of four mRNA biomarkers in saliva were significantly downregulated in GC patients compared to healthy controls. 80 Besides, salivary mRNA biomarkers has been explored in breast cancer, 81 ovarian cancer, 82 lung cancer, 83 and chronic myeloid leukemia. 84 Most of those studies indicated that combined analysis of salivary mRNA biomarkers and other known biomarkers could improve the performance of cancer detection.…”

Section: Introductionmentioning

confidence: 99%

Promising applications of human-derived saliva biomarker testing in clinical diagnostics

et al. 2023

View full text Add to dashboard Cite

Saliva testing is a vital method for clinical applications, for its noninvasive features, richness in substances, and the huge amount. Due to its direct anatomical connection with oral, digestive, and endocrine systems, clinical usage of saliva testing for these diseases is promising. Furthermore, for other diseases that seeming to have no correlations with saliva, such as neurodegenerative diseases and psychological diseases, researchers also reckon saliva informative. Tremendous papers are being produced in this field. Updated summaries of recent literature give newcomers a shortcut to have a grasp of this topic. Here, we focused on recent research about saliva biomarkers that are derived from humans, not from other organisms. The review mostly addresses the proceedings from 2016 to 2022, to shed light on the promising usage of saliva testing in clinical diagnostics. We recap the recent advances following the category of different types of biomarkers, such as intracellular DNA, RNA, proteins and intercellular exosomes, cell-free DNA, to give a comprehensive impression of saliva biomarker testing.

show abstract

Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer

Cited by 7 publications

References 57 publications

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers

Promising applications of human-derived saliva biomarker testing in clinical diagnostics

Contact Info

Product

Resources

About